HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

sergliflozin etabonate

Also Known As:

2-((4-methoxyphenyl)methyl)phenyl 6-O-ethoxycarbonylglucopyranoside

Networked: 4 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzhydryl Compounds
        sergliflozin etabonate: 4
Carbohydrates: 22023
- Glycosides: 2119
  - Glucosides: 639
    - sergliflozin etabonate: 4

Experts

1.	Dobbins, Robert L: 2 articles (06/2010 - 06/2010)
2.	Hussey, Elizabeth K: 2 articles (06/2010 - 06/2010)
3.	Layko, Debbi: 2 articles (06/2010 - 06/2010)
4.	Murray, Sharon C: 2 articles (06/2010 - 06/2010)
5.	Nunez, Derek J R: 2 articles (06/2010 - 06/2010)
6.	O'Connor-Semmes, Robin L: 2 articles (06/2010 - 06/2010)
7.	Fujimori, Yoshikazu: 2 articles (09/2009 - 05/2009)
8.	Isaji, Masayuki: 2 articles (09/2009 - 05/2009)
9.	Ishikawa-Takemura, Yukiko: 2 articles (09/2009 - 05/2009)
10.	Katsuno, Kenji: 2 articles (09/2009 - 05/2009)

Related Diseases

1.	Hyperglycemia 09/15/2009 - "Long-term treatment with sergliflozin etabonate dose-dependently improved the hyperglycemia and prevented body weight gain in the 8-week study. " 05/01/2009 - "Sergliflozin etabonate also improved postprandial hyperglycemia in neonatal streptozotocin-induced diabetic rats; whereas gliclazide did not improve it. " 09/15/2009 - "Sergliflozin etabonate, a novel oral selective low-affinity sodium glucose cotransporter (SGLT2) inhibitor, improves hyperglycemia by suppressing renal glucose reabsorption, in which SGLT2 participates as a dominant transporter. "
2.	Body Weight (Weight, Body) 06/01/2010 - "Sergliflozin etabonate produced a rapid, dose-related reduction in body weight (mean changes of -0.09, -1.55, and -1.74 kg from baseline to day 15 with placebo, sergliflozin etabonate 500 mg, and sergliflozin etabonate 1000 mg, respectively), apparently through increased urinary calorie loss rather than through osmotic diuresis. " 05/01/2009 - "In addition, sergliflozin etabonate did not affect the body weight or food intake. " 09/15/2009 - "Long-term treatment with sergliflozin etabonate dose-dependently improved the hyperglycemia and prevented body weight gain in the 8-week study. " 05/01/2009 - "These data indicate that sergliflozin etabonate could improve glycemic control without its use resulting in insulin secretion, hypoglycemia, and body weight gain, and may provide a unique approach to the treatment of diabetes."
3.	Fatty Liver 09/15/2009 - "In addition to the improvement in glycemic control, fatty liver and pancreatic beta-cell abnormalities were ameliorated in mice fed sergliflozin etabonate in the 9-week study. "
4.	Obesity 09/15/2009 - "In the present study, we examined the antidiabetic profile of sergliflozin etabonate in a diabetic model, KK-A(y) mice, with symptoms of obesity and hyperinsulinemia. "
5.	Hyperinsulinism (Hyperinsulinemia) 09/15/2009 - "In the present study, we examined the antidiabetic profile of sergliflozin etabonate in a diabetic model, KK-A(y) mice, with symptoms of obesity and hyperinsulinemia. "

Related Drugs and Biologics

1.	Streptozocin (Streptozotocin)
2.	Gliclazide (Diamicron)
3.	Hypoglycemic Agents (Hypoglycemics)
4.	Glucose (Dextrose)
5.	sergliflozin
6.	Sodium-Glucose Transport Proteins
7.	Sodium-Glucose Transporter 2 Inhibitors

Related Therapies and Procedures

1.	Glycemic Control